India saw its first success in the case of corona vaccine. This time the trial of the vaccine is starting in the human body of India. The Indian company ‘Bharat Biotech’ has developed the coronary vaccine COVAXIN. The vaccine has been approved for trial in the human body by the Drug Controller General of India on Monday.
According to Bharat Biotech, the approval was given by the Ministry of Health on the basis of a report submitted after pre-clinical studies. Phase One and Phase Two trials will start in India. The trial is set to begin in July.
The vaccine has been developed in a joint venture with ICMR and the National Institute of Virology. The strain of corona virus was isolated at the National Institute of Virology in Pune. And with that the work of making vaccines was going on.
According to the data, this company is a breakthrough in the field of vaccine development. The company still has 18 ticker patents. The most important of these is the 2009 H5N1 flu vaccine for H1N1 flu. The Flugen company has an influenza vaccine, named M2SR, which is working on a vaccine to try to make a vaccine against corona.